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mprovement of Pulmonary Function with Imatinib
esylate in Bronchiolitis Obliterans Following
llogeneic Hematopoietic Cell Transplantation
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sBronchiolitis obliterans (BO) is a late-onset non-
nfectious pulmonary complication of hematopoietic
ell transplantation (HCT) and is typically associated
ith chronic graft-versus-host disease (GVHD).
here are no effective therapies for BO and it often
eads to signiﬁcant morbidity and high mortality [1]. It
s pathologically characterized by the presence of
ronchiolar inﬂammation with submucosal and peri-
ronchiolar ﬁbrosis [2]. Imatinib, a speciﬁc tyrosine
inase inhibitor, has been shown to have antiﬁbro-
enic properties [3,4]. We therefore hypothesized that
matinib could be beneﬁcial in a case of BO compli-
ating allogeneic HCT for chronic myeloid leukemia
CML).
A 33-year-old, nonsmoking, previously healthy fe-
ale was diagnosed with Philadelphia chromosome
ositive CML in chronic phase in January 1993. She
as initially treated with hydroxyurea, with a signiﬁ-
ant decrease in white blood cell (WBC) count, but
id not achieve a complete hematologic response and
as referred for allogeneic HCT. Bone marrow bi-
psy before transplantation showed chronic phase
ML with 8% myeloblasts. Karyotype of bone mar-
ow showed the typical t(9;22)(q34;q11) in 100% of
etaphases examined. Chest radiograph and pulmo-
ary function tests (PFTs) were normal (forced expi-
atory volume in 1 second [FEV1], 2.8 L/min, 98%
redicted; forced vital capacity [FVC], 3.3 L/min,
00% predicted). She underwent allogeneic HCT using
yeloablative conditioning from a 6/6 HLA matched
ibling donor in June 1993. Conditioning regimen
onsisted of cyclophosphamide (60 mg · kg1 · d1 
days) and total body irradiation (1320 cGy in 8
ractions over 4 days) and immunosuppression in-
luded cyclosporine A (CSA) and short-course meth-
trexate. Engraftment occurred on day 29 and early
he post-transplantation course was complicated by
tage 2 acute GVHD of the skin, which responded to
opical corticosteroids. Day 100 evaluation demon-
trated a complete cytogenetic response, 100% donor
himerism, and no clinical evidence of GVHD. Chest
adiograph and PFTs continued to remain normalFEV1, 2.9 L/min, 102% predicted; FVC, 3.4 L/min,
04% predicted).
Oral, cutaneous, vaginal, and ocular chronic
VHD developed in November 1993. This was ini-
ially managed with high-dose intravenous methyl
rednisolone and oral prednisone [5] and continuation
f CSA and led to partial resolution of symptoms. She
resented with a ﬂare of GVHD at sites of previous
nvolvement in February 1994; in addition, she then
omplained of cough and exertional dyspnea. PFT
howed severe airway obstruction (FEV1, 0.6 L/min,
2% predicted; FVC, 1.2 L/min, 36% predicted) and
oss of lung volume. Computed tomogram of the chest
as consistent with the diagnosis of BO. An open lung
iopsy showed submucosal lymphocytic inﬁltration
nd, although not diagnostic of BO, excluded infec-
ions due to bacteria, fungi, acid-fast bacilli, viruses,
nd Pneumocystis. Therapy with high-dose methyl
rednisolone was reinitiated and oral prednisone and
SA were continued. Her subsequent clinical course
as characterized by remitting-relapsing chronic
VHD, progressively worsening pulmonary symp-
oms, and stable but severe airway obstruction on
erial PFTs (Figure 1). Immunosuppressants were ta-
ered off and discontinued in April 1997, although
ymptoms of dyspnea at rest, severe limitation of ex-
rcise tolerance, and need for continuous oxygen ther-
py persisted. However, CSA and steroids had to be
estarted in October 1998 after another ﬂare-up of
VHD.
The patient presented with leukocytosis (WBC
ount, 33  109/L) in May 2000, and the peripheral
lood morphology was suggestive of relapse of
hronic phase CML; this was conﬁrmed with the
etection of bcr-abl rearrangement on reverse tran-
criptase polymerase chain reaction. Chimerism anal-
sis revealed 1% to 10% donor cells in the mononu-
lear and neutrophil fractions. Immunosuppression
as tapered gradually in view of coexisting severe
hronic GVHD. No response was observed despite
chieving full donor chimerism, and hydroxyurea was
tarted to control the WBC count.Imatinib 400 mg/day was started in February 2001
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Letter to the Editor790nd followed by attainment of complete molecular
esponse. There was no increase in the number of
irculating eosinophils when imatinib was begun. Be-
ore treatment, she was dependent on a wheelchair
nd continuous use of oxygen. Her pulmonary symp-
oms rapidly improved during the ﬁrst 1 to 2 months
f imatinib treatment, with gradual elimination of her
eed for oxygen, a return to normal ambulation, and
onsiderable improvement in exercise tolerance. She
s currently almost 13 years post-transplantation with
00% donor chimerism, 5 years in complete molecu-
ar remission on imatinib, and remains oxygen free
ith acceptable exercise tolerance. There have been
o recurrences of GVHD, although she has required
hort courses of antibiotics and corticosteroids for
hat was felt to be exacerbations of asthmatic bron-
hitis.
Experimental models of BO have suggested the
ole of proﬁbrotic cytokines such as platelet-derived
rowth factor and transforming growth factor  in its
athogenesis [6,7]. In animal models, imatinib has
een shown to have signiﬁcant antiﬁbrotic properties
nd prevents and even decreases lung ﬁbrosis through
nhibition of platelet-derived growth factor tyrosine
inase and ﬁbroblast proliferation mediated by trans-
orming growth factor  [3,4]. Hence, evaluation of
he role of imatinib in the management of BO after
Figure 1. Change in preCT warrants further investigation. BEFERENCES
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